Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels.

• Tác giả: Marika Alborghetti, Simone Castorina, Giorgia Civita, Giuseppe Costanzi, Donatella De Bernardini, Sergio De Filippis, Sara Frezza, Georgios D Kotzalidis, Luana Lionetto, Ginevra Lombardozzi, Ferdinando Nicoletti, Felicia Russo, Angela Sabatino, Elio Serra, Maurizio Simmaco, Giada Trovini
• Ngôn ngữ: eng
• Ký hiệu phân loại: 912.01 Philosophy and theory
• Thông tin xuất bản: Switzerland : International journal of molecular sciences , 2025
• Bộ sưu tập: NCBI
• ID: 71769

Tóm tắt

Aripiprazole as a long-acting injectable (LAI) is initiated in oral aripiprazole-stabilised patients and needs, after first injection, 14 days supplementation of oral aripiprazole (one-injection start, OIS). Recently, an alternative two-injection start (TIS) was advanced, involving two 400 mg injections with a single 20 mg oral supplementation of aripiprazole. We tested the two regimens in patients with schizophrenia (SCZ,